Plumbagin sensitizes leukemia cells to cisplatin by promoting oxidative stress, apoptosis, and DNA damage.

Yan-Ning Chen, Jai-Wei Lee, Tsu-Ming Chien, Chia-Hung Yen, Bing-Hung Chen, Hsueh-Wei Chang

Abstract read

In one paragraph

Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan-Ning ChenGraduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Jai-Wei LeeDepartment of Tropical Agriculture and International Cooperation, National Pingtung University of Science and Technology, Pingtung 912301, Taiwan.

Tsu-Ming ChienSchool of Post-Baccalaureate Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Chia-Hung YenGraduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Bing-Hung ChenDepartment of Biotechnology, College of Life Science, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Hsueh-Wei ChangGraduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study focused on validating the synergistic antiproliferative activity and mechanism of cisplatin/plumbagin (PLB) in leukemic cells versus normal macrophages. Leukemic cells (MOLT-4) treated with cisplatin/PLB (3 μM/0.4 μM) for 24 h showed markedly reduced viability (45.51%) compared to cisplatin or PLB (81.07% or 76.36%), while normal macrophages (NR8383) retained high viability in cisplatin/PLB (~93.15%). The enhanced cytotoxicity in leukemia cells was driven by oxidative stress: the general antioxidant

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCisplatinLeukemiaNaphthoquinonesApoptosisCell Line, TumorCell ProliferationDNA DamageDrug SynergismHumansMacrophagesMembrane Potential, MitochondrialOxidative StressReactive Oxygen SpeciesCisplatinNaphthoquinonesplumbaginReactive Oxygen Speciescisplatincombined treatmentleukemiaoxidative stressplumbagin

Identifiers

PMID42328114

DOI10.7150/ijms.124444

PMCPMC13280767

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.